Afatinib and Neoplasm progression - a phase IV clinical study of FDA data

Summary:

Neoplasm progression is reported as a side effect among people who take Afatinib (afatinib), especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months also take Carboplatin, and have Lung cancer - non-small cell.

The phase IV clinical study analyzes which people have Neoplasm progression when taking Afatinib. It is created by eHealthMe based on reports of 326 people who have side effects when taking Afatinib from the FDA, and is updated regularly.

What is Afatinib?

Afatinib has active ingredients of afatinib. eHealthMe is studying from 326 Afatinib users. Check the latest studies of Afatinib.

What is Neoplasm progression?

Neoplasm progression (growth of tumour) is found to be associated with 1,067 drugs and 915 conditions by eHealthMe. Check the latest studies of Neoplasm progression.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

326 people reported to have side effects when taking Afatinib.
Among them, 12 people (3.68%) have Neoplasm progression.

Could Afatinib cause Neoplasm progression?

Among these 12 people:

How long have people been on Afatinib when they have Neoplasm progression? *

What is the gender of people who have Neoplasm progression when taking Afatinib? *

female: 90.91 %
male: 9.09 %

What is the age of people who have Neoplasm progression when taking Afatinib? *

What are other drugs people take besides Afatinib? *

Carboplatin: 2 people, 16.67%
Pemetrexed: 1 person, 8.33%
Paclitaxel: 1 person, 8.33%

What are other side effects people have besides Neoplasm progression? *

Diarrhea: 10 people, 83.33%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 9 people, 75.00%
Drug Level Increased: 9 people, 75.00%
Drug Ineffective: 9 people, 75.00%
Blood Creatine Phosphokinase Increased: 9 people, 75.00%
Overdose: 8 people, 66.67%
Malignant Neoplasm Progression (cancer tumour came back): 7 people, 58.33%
Gastrointestinal Stromal Tumor: 7 people, 58.33%
Alanine Aminotransferase Increased: 6 people, 50.00%
Acute Kidney Failure: 5 people, 41.67%

What are the existing conditions these people have? *

Lung Cancer - Non-Small Cell (lung cancer): 11 people, 91.67%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 9 people, 75.00%
Gastrointestinal Stromal Tumor: 9 people, 75.00%
Drug Resistance (reduction in effectiveness of a drug): 9 people, 75.00%
Adenocarcinoma (malignant tumour formed from glandular structures in epithelial tissue): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Afatinib and have Neoplasm progression?

- Check whether Neoplasm progression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Afatinib:

Afatinib (326 reports)

Browse all side effects of Afatinib:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Neoplasm progression:

Neoplasm progression (1,068 drugs)

Browse all the conditions that are associated with Neoplasm progression:

Neoplasm progression (915 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on afatinib (the active ingredients of Afatinib) and Afatinib (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.